KCHC-AR-2023 Final Signed - Flipbook - Page 61
Notes to the financial statements
2021/22 comparatives
At 1
April
2021
£’000
Income Expenditure
£’000
£’000
Gains/
(Losses)
£’000
Transfers
£’000
At 31
March
2022
£’000
Restricted funds
Cancer treatment
and research
244
2
-
-
2
248
Paediatric liver
laboratories
186
102
-
-
2
290
2,456
-
-
-
18
2,474
Transforming Liver
Care (TLC) Appeal
333
82
(150)
-
2
267
COVID-19 support
109
-
(101)
-
1
9
Other funds less
than £100k
212
94
(120)
-
2
188
3,540
280
(371)
-
27
3,476
Clinical funds
8,138
1,979
(438)
-
67
9,746
Fund for strategic
grants
6,903
-
-
-
-
6,903
Development of
capital projects
1,000
-
-
-
-
1,000
Office fixtures &
fittings
-
-
-
-
33
33
16,041
1,979
(438)
-
100
17,682
5,766
1,358
(2,422)
1,432
(127)
6,007
Total unrestricted
funds
21,807
3,337
(2,860)
1,432
(27)
23,689
Total funds
25,347
3,617
(3,231)
1,432
-
27,165
David Hughes
Special Trust
Total restricted
funds
Unrestricted funds
Designated
Total designated
funds
General funds
Transfers include an internal allocation to each designated and restricted fund equivalent to interest earned
based on the average value of the fund during the year.
K I N G’ S CO L L E G E H O S P I TA L C H A R I T Y A N N UA L R E P O R T A N D A CCO U N T S 2 0 2 2 / 2 3
61
